Lyell Immunopharma, Inc. · NASDAQ:LYEL
James B. Tananbaum reported a 7.60% stake in Lyell Immunopharma, Inc. (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
James B. Tananbaum reported a 7.60% stake in Lyell Immunopharma, Inc., 1,454,616 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 7.60%
- Shares
- 1,454,616
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Foresite Capital Fund IV, L.P. | 4.20% | 800,339 |
| Foresite Capital Management IV, LLC | 4.20% | 800,339 |
| Foresite Capital Fund V, L.P. | 2.50% | 477,078 |
| Foresite Capital Management V, LLC | 2.50% | 477,078 |
| Foresite Capital Opportunity Fund V, L.P. | 0.90% | 177,199 |
| Foresite Capital Opportunity Management V, LLC | 0.90% | 177,199 |
| James B. Tananbaum | 7.60% | 1,454,616 |
Source
Related
- Lyell Immunopharma, Inc.
- James B. Tananbaum
- Lyell Immunopharma, Inc. shareholders
- Schedule 13G/A · James B. Tananbaum · Aug 14, 2026
- Form 4 · Aguirre Jarrad Mattieu · Oct 13, 2026
- Form 4 · Shook David · Sep 10, 2026
- Form 4 · Seely Lynn · Aug 25, 2026
- Form 4 · Hill Stephen J. · Aug 25, 2026
- Form 4 · Lee Gary K. · Aug 25, 2026